Israel’s VBL Therapeutics has developed VB-201 – the first of a new class of oral anti-inflammatories called Lecinoxoids. VB-201 has the potential to treat immune-inflammatory diseases such as Psoriasis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis and more. The US FDA has also granted fast-track designation for VB-111, which treats GBM – an aggressive form of brain cancer.
http://www.vblrx.com/news_room/2013-05-12-vbl-therapeutics-announces-novel-mechanistic-2/
http://www.vblrx.com/news_room/2013-11-27-vbl-therapeutics-receives-fda-fast-2/